Writing in the Global Health Technologies Coalition’s “Breakthroughs” blog, Eleonora Jimenez-Levi, a senior researcher at the Treatment Action Group (TAG), examines the 2012 Report on Tuberculosis Research Funding Trends: 2005–2011,”the latest report on the state of funding for tuberculosis (TB) research and product development.” Jimenez-Levi recaps the findings and recommendations of the report and concludes, “Promising new tools are on the horizon, but without political will and adequate funding to support the development of new vaccines, diagnostics, and drugs, the world will not be able to contain the growing problem that drug-resistant TB poses, much less eliminate TB as a public health threat by 2050” (11/27).